US2014221501A1PendingUtilityA1

Therapeutic foam

63
Assignee: BTG INT LTDPriority: Nov 17, 2003Filed: Apr 9, 2014Published: Aug 7, 2014
Est. expiryNov 17, 2023(expired)· nominal 20-yr term from priority
A61P 9/00A61P 41/00A61P 9/14A61P 43/00A61K 47/02A61B 17/00008A61M 5/19A61K 47/10A61B 17/12022A61B 17/12109A61B 2017/00495A61K 9/08A61K 47/32A61B 17/00491A61K 47/20A61K 9/124A61B 17/12186A61M 5/178A61M 2202/00A61K 9/122A61K 9/0019A61K 31/08A61M 2210/086A61M 2210/12A61M 16/00B65B 3/003B65B 31/00B01F 33/50112B01F 23/235B01F 25/4512B01F 25/4523A61K 9/12A61B 17/12A61M 5/155
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.

Claims

exact text as granted — not AI-modified
1 . A foam comprising a liquid phase and a gas phase wherein
 the liquid phase comprises at least one sclerosing agent and   the gas phase consists essentially of gaseous nitrogen present in an amount ranging from 0.0001% to 0.8% by volume and at least one physiologically acceptable gas.   
     
     
         2 .- 36 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.